Boston Scientific Corporation (NYSE:BSX) Shares Purchased by Bogart Wealth LLC

Bogart Wealth LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 61,587.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,921 shares of the medical equipment provider's stock after purchasing an additional 62,819 shares during the quarter. Bogart Wealth LLC's holdings in Boston Scientific were worth $6,347,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BSX. Bank Pictet & Cie Europe AG grew its stake in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after acquiring an additional 6,264 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Boston Scientific by 13.0% in the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after acquiring an additional 575 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Boston Scientific by 109.9% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock worth $24,126,000 after acquiring an additional 141,398 shares during the last quarter. Finally, Little House Capital LLC acquired a new position in Boston Scientific in the first quarter valued at $945,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BSX shares. Leerink Partners began coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Barclays upped their target price on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Needham & Company LLC reissued a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Truist Financial upped their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Finally, Robert W. Baird upped their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $116.09.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $103.16 on Monday. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The firm has a market capitalization of $152.62 billion, a P/E ratio of 75.30, a P/E/G ratio of 2.68 and a beta of 0.68. The company's 50 day moving average price is $103.42 and its two-hundred day moving average price is $100.66.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. Boston Scientific's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 earnings per share. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total value of $5,348,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $19,077,243.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 461,970 shares of company stock valued at $47,755,193. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.